Study guide
11.3 Biologic Coverings, Dermal Regeneration Templates (Integra/Novosorb BTM), Allograft, and Xenograft
Certified Burn Registered Nurse CBRN
Track your progress as you read
Finished sections get a check mark.
1 Chapter 1: Introduction & Foundations of Burn Care
1.1 CBRN Exam Format, Eligibility, and BCEN Testing Standards 1.2 Anatomy, Histology, and Barrier Functions of the Skin 1.3 Burn Depth Classification and Jackson's Thermal Wound Zones
2 Chapter 2: Pathophysiology of Burn Injury & Systemic Response
2.1 Cellular Pathophysiology and Capillary Permeability in Burn Shock 2.2 Systemic Inflammatory Response Syndrome (SIRS) and MODS 2.3 Pathophysiology of Supraglottic, Subglottic, and Inhalational Injury 2.4 Cellular Phases of Burn Wound Healing and Scar Pathobiology
3 Chapter 3: Prehospital Triage, Primary Survey & Transfer Criteria
3.1 Initial Assessment, Primary Survey (ABCDEF), and Field Stabilization 3.2 Total Body Surface Area (TBSA) Calculation: Rule of Nines, Lund-Browder, and Palmar Method 3.3 American Burn Association (ABA) Burn Center Referral Criteria and Transport Logistics
4 Chapter 4: Fluid Resuscitation & Hemodynamic Stabilization (<72 Hours)
4.1 Fluid Resuscitation Formulas: Parkland (Baxter), Modified Brooke, and Consensus Protocols 4.2 Resuscitation Endpoints: Urine Output Titration, Base Deficit, and Hemodynamic Monitoring 4.3 Complications of Fluid Creep and Intra-Abdominal Hypertension / Abdominal Compartment Syndrome 4.4 Extremity Compartment Syndrome, Monitoring, and Emergent Escharotomy / Fasciotomy
5 Chapter 5: Airway Management & Inhalation Injury Management
5.1 Upper Airway Compromise, Indications for Early Endotracheal Intubation, and Airway Stabilization 5.2 Lower Airway Chemical Tracheobronchitis, Diagnostic Bronchoscopy, and Lung-Protective Mechanical Ventilation 5.3 Carbon Monoxide (CO) Toxicity, Cyanide Poisoning, and Specific Antidotes (Hydroxocobalamin)
6 Chapter 6: Acute Multisystem Assessment & Critical Care Management
6.1 Cardiovascular Derangements, Myocardial Depression, and Hemodynamic Optimization 6.2 Acute Kidney Injury, Rhabdomyolysis / Myoglobinuria, and Fluid-Electrolyte Shifts 6.3 Gastrointestinal Complications, Ileus, Early Enteral Nutrition, and Curling's Ulcer Prophylaxis 6.4 Neurological Impairment, Anemia of Burn Injury, Coagulopathy, and Musculoskeletal Protection
7 Chapter 7: Hypermetabolism & Nutritional Support
7.1 The Biphasic Metabolic Response: Ebb vs. Flow Phases and Persistent Hypermetabolism 7.2 Indirect Calorimetry, Caloric Equations (Curreri/Toronto), and Micronutrient / Trace Mineral Needs 7.3 Pharmacological Modulation: Propranolol, Oxandrolone, Growth Hormone, and Exercise Therapy 7.4 Stress Hyperglycemia, Intensive Insulin Protocols, and Adrenal / Thyroid Axis Dysregulation
8 Chapter 8: Pain Management in Burn Care
8.1 Pain Classification in Burns: Background, Procedural, Breakthrough, and Chronic Neuropathic Pain 8.2 Multimodal Analgesia: Opioids, Ketamine, Gabapentinoids, NSAIDs, and Regional Anesthesia 8.3 Non-Pharmacological Modalities: Virtual Reality, Cognitive Behavioral Techniques, Hypnosis, and Distraction
9 Chapter 9: Agitation, Delirium & Post-Burn Pruritus
9.1 Agitation Management, Targeted Sedation Protocols (RASS/SAS), and Circadian Rhythm Support 9.2 ICU Delirium: Risk Factors, Screening (CAM-ICU/ICDSC), Non-Pharmacological Bundles, and Medical Management 9.3 Post-Burn Itch: Histaminergic vs. Neuropathic Pruritus, Oral Antihistamines, Gabapentin, and Topical Emollients
10 Chapter 10: Burn Wound Assessment, Topical Antimicrobials & Dressings
10.1 Serial Wound Bed Assessment, Tissue Perfusion, and Documentation Standards 10.2 Topical Antimicrobial Formulations: Silver Sulfadiazine, Mafenide Acetate, Silver Nitrate, and Modern Silver Dressings 10.3 Wound Bed Preparation: Surgical, Enzymatic (Collagenase/Bromelain), Autolytic, and Mechanical Debridement 10.4 Modern Dressings, Hydrogels, Foam Dressings, Negative Pressure Wound Therapy (NPWT), and Moisture Retentive Balances
11 Chapter 11: Surgical Excision, Skin Grafting & Wound Closure
11.1 Principles of Early Tangential vs. Fascial Surgical Excision and Blood Conservation 11.2 Split-Thickness and Full-Thickness Autografting: Mesh Expansion Ratios vs. Sheet Grafts 11.3 Biologic Coverings, Dermal Regeneration Templates (Integra/Novosorb BTM), Allograft, and Xenograft 11.4 Autologous Cell Suspensions (ReCell), Cultured Epithelial Autografts (CEA), and Donor Site Management
12 Chapter 12: Burn Sepsis, Infection Control & Antimicrobial Therapy
12.1 Burn Center Infection Control: Contact Precautions, Hydrotherapy Sanitation, and Environmental Controls 12.2 Differentiating Hypermetabolic SIRS from Burn Sepsis: ABA Consensus Sepsis Criteria 12.3 Common Burn Pathogens (Pseudomonas, MRSA, Acinetobacter, Candida, Aspergillus) and Empiric Coverage 12.4 Invasive Burn Wound Infection: Clinical Signs, Quantitative Biopsy (>10^5 CFU/g), and Histopathological Invasion
13 Chapter 13: Specific Burn Etiologies: Electrical, Chemical & Cold Injuries
13.1 Electrical Burn Injuries: High-Voltage vs. Low-Voltage, Arc/Flash, Cardiac Monitoring, and Deep Muscle Necrosis 13.2 Chemical Injuries: Acids (Coagulation Necrosis), Alkalis (Liquefactive Necrosis), Hydrofluoric Acid (Calcium Gluconate), and Decontamination 13.3 Radiation Burns, Cutaneous Radiation Syndrome, Cold Injuries (Frostbite Triage and Thawing Protocols), and Vasodilator Therapy
14 Chapter 14: Special Burn Populations & Cutaneous Syndromes
14.1 Pediatric Burn Resuscitation (Maintenance Fluids + D5W), Surface Area Dynamics, and Non-Accidental Trauma Screening 14.2 Geriatric Burn Care: Thin Dermis, Altered Fluid Tolerance, Pre-existing Comorbidities, and Mortality Prognostication (Baux Score) 14.3 Burn Injury in Pregnancy: Maternal Physiology, Resuscitation, and Fetal Surveillance 14.4 Severe Cutaneous Adverse Reactions: Stevens-Johnson Syndrome (SJS), Toxic Epidermal Necrolysis (TEN), SCORTEN, and Specialized Burn Unit Nursing 14.5 Necrotizing Soft Tissue Infections and Friction/Shear Injuries
15 Chapter 15: Rehabilitation, Scar Management & Reconstruction
15.1 Anti-Deformity Positioning, Range-of-Motion Exercises, and Custom Splinting Across Major Joints 15.2 Hypertrophic Scarring Mechanisms, Myofibroblasts, and Vancouver Scar Scale (VSS) Assessment 15.3 Custom Pressure Garments (20-30 mmHg), Silicone Sheeting, Fractional CO2 Laser Resurfacing, and Contracture Release 15.4 Psychosocial Recovery, Post-Traumatic Stress Disorder (PTSD), Body Image Adaptation, Peer Support (Phoenix Society), and School/Work Reintegration 15.5 Discharge Teaching, Transition to Ambulatory Care, and Home Management
16 Chapter 16: Professional Practice, Ethics, Quality & Disaster Triage
16.1 Ethical Dilemmas in Burn Critical Care, Surrogate Decision-Making, Futility, and Palliative / End-of-Life Symptom Management 16.2 Interprofessional Burn Team Roles, Multidisciplinary Rounds, Structured Handoffs, and Patient/Family Advocacy 16.3 Burn Quality Improvement, American Burn Association (ABA) Verification Standards, and National Burn Repository (NBR) Benchmarking 16.4 Diversity, Equity, Inclusion, and Intraprofessional Nursing Development 16.5 Community Outreach, Burn Prevention Education, and Home Safety 16.6 Mass Casualty Burn Disasters, Secondary Triage Schemes (ABA/ABLS Triage Matrix), Surge Capacity, and CBRN/HAZMAT Emergency Response
11.3 Biologic Coverings, Dermal Regeneration Templates (Integra/Novosorb BTM), Allograft, and Xenograft
Key Takeaways Explain This Topic AI
Biologic coverings and dermal regeneration templates serve as essential temporary or staged permanent bridging therapies when autograft donor sites are exhausted, limited, or when the patient cannot physiologically tolerate prolonged autograft harvesting.
Allograft (cadaveric homograft) is the gold-standard temporary biologic covering; it vascularizes and integrates with the host bed, halting evaporative fluid and protein loss, eradicating wound pain, controlling microbial colonization, and preparing the wound bed until immune rejection occurs at 2 to 3 weeks.
Xenograft (porcine heterograft) functions as a temporary, non-vascularizing biological dressing primarily for clean, superficial-to-mid dermal partial-thickness burns; it must be exchanged or removed every 3 to 5 days to prevent sub-dressing infection and inflammatory rejection.
Integra Bilayer Matrix is an engineered dermal regeneration template consisting of a porous bovine collagen/chondroitin-6-sulfate scaffold covered by a temporary silicone pseudo-epidermis; Stage 1 guides host cellular infiltration to create a vascularized 'neodermis' over 14 to 21 days (turning peach/salmon color), after which Stage 2 delaminates the silicone for ultra-thin STSG placement.
Biodegradable Temporizing Matrix (Novosorb BTM) is a fully synthetic polyurethane open-cell foam template that is highly resistant to infection in contaminated beds, integrating over 3 to 4 weeks before sealing film delamination and thin autografting.
Last updated: August 2026
11.3 Biologic Coverings, Dermal Regeneration Templates (Integra/Novosorb BTM), Allograft, and Xenograft
Core Knowledge: In extensive major thermal injuries ( > 40 % to 50 % TBSA >40\%\text{ to }50\%\text{ TBSA} > 40% to 50% TBSA ), full-thickness wound excision rapidly exhausts the patient's available autologous donor skin. Under these life-threatening circumstances, the burn team must deploy temporary biological coverings and engineered dermal regeneration templates to achieve immediate physiological wound closure. The Certified Burn Registered Nurse (CBRN) must master the biological mechanics, staged surgical workflows, color maturation indicators, and complication management associated with these advanced skin substitutes.
1. Classification & Roles of Skin Substitutes
Skin substitutes are classified across multiple clinical and structural dimensions: temporary vs. permanent, biological vs. synthetic, and cellular vs. acellular. SPECTRUM OF SKIN SUBSTITUTES
- ┌────────────────────────────────────────────────────────────────────────┐
- │ [1] TEMPORARY BIOLOGICAL COVERINGS (Bridge to Autografting) │
- │ • Allograft (Homograft): Cryopreserved/fresh cadaveric skin │
- │ • Xenograft (Heterograft): Porcine skin │
- │ • Amniotic Membrane: Human placental membrane │
- ├────────────────────────────────────────────────────────────────────────┤
- │ [2] DERMAL REGENERATION TEMPLATES (Engineered Scaffolds) │
- │ • Integra Bilayer Matrix: Bovine collagen + GAG + Silicone layer │
- │ • Novosorb BTM: Biodegradable synthetic polyurethane foam + Film │
- │ • Matriderm: Bovine collagen + elastin matrix (single-stage STSG) │
- │ • AlloDerm: Acellular human cadaveric dermal matrix (ADM) │
- ├────────────────────────────────────────────────────────────────────────┤
- │ [3] PERMANENT CELLULAR / EPIDERMAL REPLACEMENTS │
- │ • Autologous Split-Thickness Skin Graft (STSG) / FTSG │
- │ • Cultured Epithelial Autografts (CEA / Epicel) │
- │ • Autologous Cell Suspension (ReCell) │
- └────────────────────────────────────────────────────────────────────────┘
- Physiological Functions of Immediate Wound Coverage
Whether temporary or permanent, closing an open excised burn wound achieves vital homeostatic goals:
Restores the Evaporative Barrier: Halts massive insensible water loss (which can exceed 3 , 000 to 5 , 000 mL/m 2 /day 3,000\text{ to }5,000\text{ mL/m}^2\text{/day} 3 , 000 to 5 , 000 mL/m 2 /day in open burns) and terminates evaporative heat loss, preserving core body temperature.
Halts Protein & Electrolyte Exudation: Prevents continuous transudative loss of albumin, immunoglobulins, and micronutrients across raw capillary beds.
Eliminates Pain: Protects exposed dermal nerve terminals from ambient airflow, temperature shifts, and mechanical friction.
Suppresses Microbial Proliferation: Re-establishes a physical barrier that prevents airborne pathogen deposition and reduces surface colonization.
Stimulates Angiogenesis: Releases cytokines and growth factors that prepare suboptimal wound beds for future autografting.
- 2. Temporary Biologic Coverings: Allograft vs. Xenograft
- Allograft (Homograft / Cadaveric Skin)
Allograft is harvested from human cadaveric donors within 24 hours of death, screened rigorously for infectious diseases (HIV, Hepatitis B/C, Syphilis), and preserved via cryopreservation (liquid nitrogen at − 196 ∘ C -196^\circ\text{C} − 19 6 ∘ C ) or glycerol preservation.
Biological Integration: Allograft is the gold-standard temporary biological covering . It undergoes true biological plasmatic imbibition and capillary inosculation , establishing functional microvascular blood flow with the host recipient bed within 48 to 72 hours.
Clinical Indications:
Immediate temporary coverage of massive excised burn wounds when autograft donor sites are unavailable.
The "Test Graft": Applied to questionable, heavily colonized, or freshly debrided wound beds to verify bacterial control and vascular readiness. If the allograft "takes" (becomes pink and adherent), the wound bed is deemed ready for definitive autografting.
Sandwich Technique (Alexander Technique): Applied as an unmeshed or 1:1.5 meshed sheet directly over widely meshed (1:3 to 1:6) autografts. The allograft protects the open interstitial diamond gaps from desiccation and infection while autologous keratinocytes migrate beneath it.
Rejection Timeline: Because cadaveric skin expresses foreign Human Leukocyte Antigens (HLA Class I and II) on epidermal and endothelial cells, the recipient's cell-mediated immune system (CD4+ and CD8+ T lymphocytes) mounts an acute rejection response. Cryopreserved allograft undergoes immune rejection typically within 14 to 21 days (fresh allograft rejects in 7 to 10 days; immunosuppressed patients may retain it for 4 to 6 weeks). The allograft must be surgically excised or stripped before necrotic rejection leads to suppurative wound infection.
Xenograft (Heterograft / Porcine Skin)
Xenograft is harvested from animal sources, predominantly porcine (pig) dermis and epidermis , and processed via lyophilization (freeze-drying) or glutaraldehyde cross-linking.
Biological Behavior: Xenograft does NOT undergo vascular inosculation or establish direct blood flow with the host bed. It adheres mechanically via fibrin bonding to provide a biological "bandage."
Clinical Indications: Clean, superficial to mid-dermal partial-thickness burns (especially pediatric scalds), donor sites, and temporary coverage of cleanly debrided wounds awaiting immediate autografting.
Nursing Management & Complications: Because xenograft does not revascularize, it rapidly desiccates and hardens. It must be removed and replaced every 3 to 5 days . If left in place too long, host leukocyte infiltration and bacterial proliferation beneath the non-viable pig skin trigger severe sub-dressing suppuration and wound conversion.
Comparative Analysis: Allograft vs. Xenograft
- Clinical Characteristic Allograft (Cadaveric Homograft) Xenograft (Porcine Heterograft)
- Tissue Origin Human cadaveric skin Porcine (pig) skin
- Vascular Inosculation Yes ; establishes true microvascular flow No ; purely mechanical adherence via fibrin
- Rejection / Lifespan Cell-mediated rejection at 14 to 21 days Non-vascularized; must be changed in 3 to 5 days
- Pain & Fluid Control Superior ; complete physiological seal Excellent for clean partial-thickness burns
- Wound Bed Preparation Cleanses and prepares bed for autografting Acts as a temporary protective dressing
- Risk of Sepsis if Retained High once rejected; must be removed Very High if left > 5 >5 > 5 days (suppuration)
- 3. Dermal Regeneration Templates: Integra Bilayer Matrix
Integra Bilayer Wound Matrix is an advanced, acellular dermal regeneration template designed to reconstruct a functional, permanent neodermis in deep partial- and full-thickness burns where native dermis has been completely destroyed. INTEGRA BILAYER MATRIX ARCHITECTURE
- [ Temporary Layer ] ══════════════════════════════════════ ◄── 0.1 mm Polysiloxane (Silicone)
- (Mechanical seal, moisture barrier)
- [ Dermal Template ] ▒ ▒ ▒ ▒ ▒ ▒ ▒ ▒ ▒ ▒ ▒ ▒ ▒ ▒ ▒ ▒ ▒ ▒ ▒ ◄── Bovine Collagen Type I +
- (Porous scaffold 70–120 μm; Chondroitin-6-Sulfate (GAG)
- host fibroblasts & vessels invade)
- ════════════════════ ══════════════════════════════════════
- [ Excised Bed ] ██████████████████████████████████████ ◄── Healthy viable wound bed
- Structural Anatomy and Mechanism
The Inner Dermal Layer (Scaffold): A 1.0 to 2.0 mm thick porous matrix composed of cross-linked bovine tendon Type I collagen and glycosaminoglycan (chondroitin-6-sulfate) derived from shark cartilage, with a calibrated pore size of 70 to 120 microns . When placed on an excised wound, host fibroblasts, macrophages, and capillary endothelial cells migrate into the scaffold. Over 2 to 3 weeks, host fibroblasts deposit endogenous human collagen while endogenous enzymes slowly biodegrade the bovine matrix, creating a living, vascularized "neodermis."
The Outer Epidermal Layer (Silicone): A 0.1 mm semi-permeable polysiloxane (silicone) membrane bonded to the collagen. It functions as a temporary synthetic epidermis, controlling water vapor loss, providing mechanical strength, and barring bacterial invasion.
Staged Surgical Protocol & Color Maturation
Integra requires a structured two-stage surgical procedure separated by a 2- to 3-week neovascularization window: TWO-STAGE INTEGRA SURGICAL WORKFLOW
- ┌────────────────────────────────────────────────────────────────────────┐
- │ STAGE 1: Surgical Excision & Template Fixation (Day 0) │
- │ • Radical or tangential excision down to pristine, viable tissue │
- │ • Apply Integra matrix; fix with staples or sutures │
- │ • Bolster dressing or Negative Pressure Wound Therapy (NPWT at -125) │
- ├────────────────────────────────────────────────────────────────────────┤
- │ INTERMEDIATE NEOVASCULARIZATION PHASE (Days 1 to 21) │
- │ • Days 1–7: Matrix appears reddish-pink (erythrocyte penetration) │
- │ • Days 7–14: Matrix transitions to pale yellow / amber │
- │ • Days 14–21:Matrix becomes PEACH / SALMON / APRICOT (mature neodermis)│
- │ • Capillary refill visible through translucent silicone │
- ├────────────────────────────────────────────────────────────────────────┤
- │ STAGE 2: Silicone Delamination & Thin Autografting (Days 14 to 21) │
- │ • Remove surgical staples along margins │
- │ • Gently peel/delaminate the silicone membrane from the neodermis │
- │ • Harvest and apply an ULTRA-THIN STSG (0.004 to 0.006 inches) │
- │ • Secure with bolster or NPWT; rapid epithelial take occurs in 3–5 days│
- └────────────────────────────────────────────────────────────────────────┘
- Complications and Nursing Management of Integra
Sub-Silicone Seroma and Hematoma Accumulation:
Pathology: Blood or serous fluid collects between the silicone sheet and the collagen matrix, separating the silicone and creating a high risk for infection and matrix failure.
Nursing Intervention: Inspect the template daily. If fluid collects, perform sterile aspiration or fenestration using an 18- or 20-gauge needle or small micro-slit with a #11 blade over the collection. Gently express the fluid with a sterile cotton swab and re-apply compressive bolster dressings.
Infection and Matrix Lysis:
Pathology: Bacterial colonization beneath the silicone releases proteases that rapidly lyse the collagen scaffold. Infection is recognized by a transition of the matrix from peach/salmon to cloudy gray, dark brown, or green , accompanied by foul odor, purulence, and spontaneous floating of the silicone layer.
Nursing Intervention: Infection mandates immediate surgical notification, localized or complete removal (delamination) of the infected silicone/matrix, wound culture collection, and initiation of topical antimicrobial soaks (e.g., silver nitrate 0.5%, mafenide acetate 5% solution, or dilute sodium hypochlorite/Dakin's solution).
4. Synthetic Biodegradable Templates: Novosorb BTM
Novosorb Biodegradable Temporizing Matrix (BTM) is a fully synthetic, open-cell polyurethane dermal scaffold designed to overcome the biological limitations and infection risks of animal-derived matrices.
Composition: Composed entirely of a biodegradable polyurethane open-cell foam (with interconnecting 200–300 micron pores) bonded to a non-porous temporary polyurethane sealing membrane. Contains zero biological or animal-derived components , eliminating risks of prion transmission or religious/cultural objections.
Key Clinical Advantage (Infection Resilience): Unlike collagen matrices (which dissolve rapidly when exposed to bacterial proteases), Novosorb BTM is highly resistant to microbial degradation . If localized infection occurs, the template does not lyse; the silicone/polyurethane seal can be fenestrated, the collection irrigated with antimicrobial solutions, and the synthetic scaffold preserved while tissue ingrowth continues.
Integration & Staging: Host fibrovascular tissue integrates through the polyurethane foam over 3 to 4 weeks (21 to 28 days) . Once fully integrated (demonstrating a robust, vascularized red tissue bed with positive capillary refill), the sealing membrane is delaminated, the superficial surface lightly dermabraded or debrided, and an ultra-thin STSG (0.005 to 0.008 inches) is applied.
5. Nursing Surveillance Protocols for Dermal Templates
Continuous Bolster Maintenance: Dermal templates require continuous, uniform contact with the recipient wound bed. Negative Pressure Wound Therapy (NPWT at continuous − 75 to − 125 mmHg -75\text{ to }-125\text{ mmHg} − 75 to − 125 mmHg ) is the gold-standard dressing over Integra and BTM. Ensure the NPWT seal is airtight; loss of vacuum allows shear motion and fluid pooling.
Shear Stress Mitigation: Prevent any friction or shearing forces across the template during patient transfers, repositioning, or linen changes. Keep adjacent joints rigidly splinted in anti-deformity positions until Stage 2 autografting is complete.
Systematic Color Tracking: Document the chronological color progression of the matrix every shift (from initial red, to pale yellow, to mature peach/salmon). Any sudden appearance of dark maroon, black, cloudy gray, or yellow-green exudate must be escalated immediately.